|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.01 EUR | -0.83% |
|
+0.90% | -2.70% |
| 15/06 | Bayer Receives FDA Approval for Ambelvist for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity | CI |
| 15/06 | Bayer Receives U.S. Approval for Gadoquatrane |  |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 49.5 | +36.33% | 19 | ||||||
| 1,215.79 | +7.65% | 29 | ||||||
| 252.87 | +7.3% | 23 | ||||||
| 253.55 | +14.42% | 29 | ||||||
| 360.76 | +10.63% | 17 | ||||||
| 154.88 | +2.19% | 21 | ||||||
| 221.03 | +24.61% | 21 | ||||||
| 311.78 | +9.17% | 23 | ||||||
| 352.77 | +0.64% | 30 | ||||||
| 157.57 | +26.77% | 28 | ||||||
| 29.19 | +12.26% | 27 | ||||||
| 63.08 | +12.16% | 25 | ||||||
| 548.69 | +21.81% | 29 | ||||||
| 96.7 | +28.02% | 23 | ||||||
| 20.77 | +6.06% | 19 | ||||||
| 9,973.33 | +34.27% | 15 | ||||||
| 6,106.87 | +20.02% | 15 | ||||||
| 81.14 | +69.46% | 16 | ||||||
| 40.9 | +21.4% | 10 | ||||||
| 4.169 | +24.41% | 17 | ||||||
| Average | 1,014.77 | +19.48% | 22 | ||||||
| Weighted average by Cap. | 703.82 | +12.63% | 24 |
- Stock Market
- Stocks
- BAYN Stock
- Sector Bayer AG
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition